Akums Drugs & Pharmaceuticals: Business Overview & Financial Analysis

Akums Drugs & Pharmaceuticals is an integrated pharmaceutical CDMO and manufacturing enterprise headquartered in New Delhi. Promoted by Sanjeev Jain and Sandeep Jain, the company is India's largest contract development and manufacturing organization (CDMO) focused on pharmaceutical formulations, alongside active pharmaceutical ingredient (API) synthesis and branded consumer formulations. Managing automated production plants across Haridwar (Uttarakhand), Baddi (Himachal Pradesh), and Lalru (Punjab), Akums Drugs manufactures oral solids, liquid orals, sterile injectables, hormonal formulations, and specialized active pharmaceutical ingredients for leading domestic pharmaceutical majors, multinational healthcare enterprises, and international export channels.

Business Segment Revenue Breakdown of Akums Drugs & Pharmaceuticals (FY2026)

Akums Drugs & Pharmaceuticals structures its operational manufacturing turnover across contract development and manufacturing (CDMO), active pharmaceutical ingredients (APIs), and branded consumer formulations.

• CDMO Services Division – 77.5% of Total Operating Revenue
• Branded Formulations Division – 14.2% of Total Operating Revenue
• Active Pharmaceutical Ingredients (API) Division – 8.3% of Total Operating Revenue
• Total Consolidated Revenue from Operations (FY2026) – Rs 4,285.40 crore (+12.8% YoY)

The CDMO business serves as the core revenue and profitability driver, providing end-to-end formulation development and large-scale contract manufacturing. Branded formulations and specialized API manufacturing units support business diversification and client integration.

Therapeutic Portfolio & Formulation Capabilities of Akums Drugs & Pharmaceuticals (FY2026)

Akums Drugs & Pharmaceuticals aligns its formulation processing capabilities across major chronic, sub-chronic, and acute therapeutic domains.

• Anti-Infective & Antibiotics Share – 28.5% of Total Formulation Production
• Gastroenterology & Pain Management Share – 24.2% of Total Formulation Production
• Cardiovascular, Anti-Diabetes & CNS Share – 22.0% of Total Formulation Production
• Vitamins, Minerals & Dietary Supplements Share – 15.8% of Total Formulation Production
• Dermatology & Respiratory Care Share – 9.5% of Total Formulation Production

Formulation development spans high-volume oral solid tablets, hard gelatin capsules, liquid syrups, dry syrups, lyophilized injectables, hormonal tablets, and eye/ear drops. Chronic therapeutic verticals in cardiovascular, anti-diabetes, and CNS care drive steady volume orders.

Manufacturing Facilities Scale & Approvals of Akums Drugs & Pharmaceuticals (FY2026)

Akums Drugs & Pharmaceuticals operates specialized formulation and synthesis complexes certified by domestic and international health regulatory authorities.

• Operational Manufacturing Units Base – 12 specialized manufacturing plants in India
• Primary Manufacturing Locations – Haridwar (Uttarakhand), Baddi (Himachal Pradesh), and Lalru (Punjab)
• Commercialized Formulation SKUs Portfolio – 4,000+ commercialized formulation SKUs
• Active CDMO Client Relationships – 1,500+ pharmaceutical and healthcare brand clients
• Global Regulatory Site Approvals – WHO-GMP, USFDA, EU-GMP, TGA (Australia), and USFDA-aligned suites

Manufacturing operations in Haridwar and Baddi process bulk formulation orders, supported by in-house quality control testing laboratories. International regulatory accreditations enable formulation exports to semi-regulated and regulated overseas markets.

Geographic Revenue Mix & Export Footprint of Akums Drugs & Pharmaceuticals (FY2026)

Akums Drugs & Pharmaceuticals balances direct domestic contract supply in India with direct drug exports across global healthcare markets.

• Domestic Indian Market Sales Share – 82.5% of Total Operating Revenue
• Overseas International Exports Channel Share – 17.5% of Total Operating Revenue
• Primary Overseas Export Destinations – CIS Countries, Latin America, South-East Asia, Africa, and Middle East
• Global Footprint Coverage – Direct exports to 50+ countries globally

Domestic market sales contribute over eight-tenths of total operational turnover, supplying 40 out of the top 50 pharmaceutical enterprises in India. Overseas exports deliver finished formulations and APIs to emerging pharmaceutical markets.

Latest Quarterly Financial Performance of Akums Drugs & Pharmaceuticals (Q1 FY2027)

Akums Drugs & Pharmaceuticals recorded top-line revenue expansion and operating margin recovery during the first quarter of FY2027.

• Consolidated Revenue from Operations – Rs 1,125.40 crore (+13.5% YoY)
• Consolidated Operating EBITDA – Rs 168.50 crore (+18.2% YoY)
• Operating EBITDA Margin – 14.97% (+59 bps YoY)
• Consolidated Net Profit After Tax (PAT) – Rs 92.40 crore (+22.5% YoY)
• CDMO Tonnage Execution Volume – 2.85 billion dosage units

First-quarter operating revenue rose 13.5% year-on-year to Rs 1,125.40 crore, supported by high CDMO order book execution across oral solids and sterile injectables. Consolidated Net Profit After Tax reached Rs 92.40 crore, while operating EBITDA margins expanded to 14.97%.

Consolidated Annual Financial Performance of Akums Drugs & Pharmaceuticals (FY2026)

Akums Drugs & Pharmaceuticals delivered full-year turnover expansion and operating profit growth for full financial year FY2026.

• Full Year Consolidated Revenue from Operations – Rs 4,285.40 crore (+12.8% YoY)
• Full Year Consolidated Operating EBITDA – Rs 625.20 crore (+16.5% YoY)
• Full Year Operating EBITDA Margin – 14.58% (+46 bps YoY)
• Consolidated Net Profit After Tax (PAT) – Rs 325.40 crore (+21.2% YoY)
• Return on Capital Employed (ROCE) – 18.2%

Full-year operating turnover crossed Rs 4,280 crore in FY2026, as consolidated Net Profit After Tax expanded 21.2% to Rs 325.40 crore. Operational execution was supported by CDMO volume scaling, raw material cost stabilization, and plant capacity utilization gains.

Balance Sheet Structure & Financial Health Ratios of Akums Drugs & Pharmaceuticals (Q1 FY2027)

Akums Drugs & Pharmaceuticals operates a disciplined capital structure supported by operational cash flow conversion and low financial debt gearing.

• Net Financial Debt to Equity Ratio – Low Debt (0.18x)
• Total Cash, Bank Balances & Liquid Investments – Rs 580.00 crore
• Total Consolidated Net Worth Base – Rs 2,850.00 crore
• Return on Equity (ROE) – 14.5%
• Working Capital Cycle – 58 days

The enterprise closed Q1 FY2027 with a consolidated net worth base of Rs 2,850.00 crore and low debt gearing of 0.18x. Internal operational cash flow generation supports ongoing capital expenditure plans without reliance on long-term debt additions.

Capex Pipeline & Facility Expansion Roadmap of Akums Drugs & Pharmaceuticals (FY2027–FY2028)

Akums Drugs & Pharmaceuticals executes capital allocation outlays to construct injectable formulation blocks and expand API manufacturing lines.

• Total Planned Multi-Year Capex Outlay – Rs 350–400 crore over FY2027–FY2028
• Injectable & Sterile Suites Expansion Outlay – Setting up high-capacity sterile vial and ampoule lines at Haridwar
• API Plant Modernization Outlay – Scaling advanced active pharmaceutical ingredient synthesis capacity at Lalru
• R&D & Complex Formulation Suite Outlay – Developing novel drug delivery systems (NDDS) and liposomal formulations
• Funding Method – 85% funded through internal operational cash accruals and 15% debt facilities

Annual capital expenditure is budgeted at Rs 350–400 crore over FY2027–FY2028 to expand sterile injectable suites and modernize API facilities. Internal operational cash flows fully fund the majority of planned expansions.

Strategic Outlook & Management Commentary of Akums Drugs & Pharmaceuticals (Q1 FY2027 Concall)

Management guidance outlines strategic priorities centered on CDMO volume growth acceleration, export expansion, and margin protection.

• Management targets achieving a 14%–16% annual top-line revenue CAGR over the FY2027–FY2029 period.
• Operating EBITDA margins are guided to sustain within the 15.0%–16.5% corridor through product mix execution.
• International exports revenue share in total turnover is targeted to reach 22% over the next 3 years.
• Complex injectable and hormonal formulation lines will be commercialized to drive client order values.
• Capital allocation strategy will maintain net debt to equity below 0.30x while funding brownfield facility expansions.

Management anticipates rising domestic pharmaceutical outsourcing and global supply-chain diversification to support CDMO contracts. Operational focus centers on commissioning sterile injectable additions, expanding export registrations, and preserving balance sheet health.

Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters.

Sources & References

1. Akums Drugs & Pharmaceuticals Integrated Annual Report FY2025–26 & Stock Exchange Filings
2. Akums Drugs & Pharmaceuticals Corporate Announcements & Exchange Disclosures
3. Ticker Finology Akums Drugs & Pharmaceuticals Page 

Disclaimer
The information presented above on Akums Drugs & Pharmaceuticals has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Akums Drugs & Pharmaceuticals page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.